Today, Goldman Sachs Group Inc. Reiterates $26.00 Price Target for Horizon Pharma Inc. (HZNP)

Today, Goldman Sachs Group Inc. Reiterates $26.00 Price Target for Horizon Pharma Inc. (HZNP)

Goldman Sachs Group Inc. set a $26.00 price objective on Horizon Pharma Inc. (NASDAQ:HZNP) in a research report sent to investors on Wednesday. The firm currently has a a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on HZNP. Brean Capital restated a buy rating and set a $30.00 target price on shares of Horizon Pharma in a research report on Tuesday, August 9th. Zacks Investment Research upgraded Horizon Pharma from a hold rating to a buy rating and set a $25.00 price objective for the company in a report on Wednesday, August 10th. Guggenheim reiterated a buy rating and issued a $30.00 price objective on shares of Horizon Pharma in a report on Tuesday, August 23rd. BMO Capital Markets reiterated an outperform rating and issued a $30.00 price objective (up from $29.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. Finally, Piper Jaffray Cos. reiterated an overweight rating and issued a $33.00 price objective (down from $34.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Horizon Pharma currently has an average rating of Buy and an average target price of $29.92.

Shares of Horizon Pharma (NASDAQ:HZNP) opened at 17.52 on Wednesday. The firm has a 50-day moving average price of $18.68 and a 200-day moving average price of $17.87. The company’s market capitalization is $2.82 billion. Horizon Pharma has a one year low of $12.86 and a one year high of $23.70.

Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The business earned $257.40 million during the quarter, compared to analysts’ expectations of $235.43 million. During the same period in the previous year, the business earned $0.39 earnings per share. The firm’s revenue was up 48.9% on a year-over-year basis. Equities analysts forecast that Horizon Pharma will post $2.15 earnings per share for the current year.

In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in HZNP. FMR LLC raised its position in shares of Horizon Pharma by 1.7% in the second quarter. FMR LLC now owns 23,353,416 shares of the biopharmaceutical company’s stock valued at $384,631,000 after buying an additional 401,302 shares in the last quarter. Deerfield Management Co. raised its position in shares of Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock valued at $227,676,000 after buying an additional 2,055,460 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Horizon Pharma by 7.5% in the second quarter. Vanguard Group Inc. now owns 10,569,177 shares of the biopharmaceutical company’s stock valued at $174,074,000 after buying an additional 737,812 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Horizon Pharma by 127.3% in the second quarter. BlackRock Fund Advisors now owns 6,678,136 shares of the biopharmaceutical company’s stock valued at $109,989,000 after buying an additional 3,740,449 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Horizon Pharma by 28.6% in the second quarter. JPMorgan Chase & Co. now owns 4,341,698 shares of the biopharmaceutical company’s stock valued at $71,508,000 after buying an additional 964,505 shares in the last quarter. 85.26% of the stock is owned by hedge funds and other institutional investors.

About Horizon Pharma

Related posts

Leave a Comment